Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price decreased by equities researchers at Mizuho from $112.00 to $108.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Mizuho’s price objective indicates a potential upside of 30.20% from the company’s previous close. Other […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price lowered by investment analysts at Mizuho from $112.00 to $108.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Mizuho’s target price points to a potential upside of 30.92% from the company’s current price. Other […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective dropped by equities researchers at Royal Bank of Canada from $126.00 to $123.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank of Canada’s price target points to a potential upside of 46.50% […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective lifted by equities researchers at Guggenheim from $110.00 to $125.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 54.02% from the stock’s […]
UBS Group began coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research note published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $111.00 price target on the stock. AXSM has been the subject of a number of other research reports. Royal Bank of Canada assumed coverage on […]